PRKAA2 and colitis: Furthermore, the AMPK activator AICAR has been demonstrated to attenuate disease progression in several in vivo models of inflammation including a rat model of autoimmune encephalomyelitis, a mouse lung injury model and a murine model of colitis [8–10].